1237744-13-6
Chemical Structure
QNZ46
- CAS No.: 1237744-13-6
- Formula:C24H17N3O6
- Molecular Weight:443.41
IUPAC Name: (E)-4-(6-methoxy-2-(3-nitrostyryl)-4-oxoquinazolin-3(4H)-yl)benzoic acid
InChIKey: GNLVJIICVWDSNI-LFYBBSHMSA-N
SMILES: O=C(O)C1=CC=C(N2C(/C=C/C3=CC=CC([N+]([O-])=O)=C3)=NC4=C(C=C(OC)C=C4)C2=O)C=C1
Biological Activity: QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
QNZ46 | 99.46% | QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hansen KB, et al. Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-3661. [Content Brief]
- [2]. Doyle S, et al. Vesicular glutamate release from central axons contributes to myelin damage. Nat Commun. 2018 Mar 12;9(1):1032. [Content Brief]
- [3]. Guo F, et al. Sevoflurane acts as an antidepressant by suppression of GluN2D-containing NMDA receptors on interneurons. Br J Pharmacol. 2024 Sep;181(18):3483-3502. [Content Brief]
